CliffBio
small molecule

ADEMPAS

RIOCIGUAT

Loss of exclusivityFebruary 2034latest FDA-listed patent expiry
CompanyBayer Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameADEMPAS
Active ingredientRIOCIGUAT
Strength2.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2013
Marketing statusRX

Listed patents

PatentExpiresType
12503469February 2034product
10662188February 2034substance, product
11203593February 2034substance, product
7173037December 2026substance, product

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ADEMPAS patent cliff — loss of exclusivity February 2034 | CliffBio